Since patients with COPD often have other comorbidities, researchers sought to understand patient adherence to maintenance COPD medications and adherence to treat other chronic conditions.
Adherence to medications can be an issue in all disease types, but it’s especially challenging in chronic obstructive pulmonary disease (COPD). While there are medications available to control symptoms of COPD, reduce exacerbations, and improve the overall health status of patients, medication adherence for COPD remains well below the average level.
Some previously established reasons for low adherence to COPD medications are the daily variations in symptoms, patient knowledge and beliefs, socioeconomic factors, and the fact that COPD patients often have other comorbidities. Since patients with COPD often have other comorbidities, researchers sought to understand patient adherence to maintenance COPD (mCOPD) medications and adherence to treat other chronic conditions. The study was published in the International Journal of COPD
“Understanding the relationship may provide further insight into the reasons for suboptimal adherence rates for COPD medications,” the authors wrote.
The researchers studied claims data from the Humana Research Database from January 1, 2008, to December 31, 2012. Patients in the study had a COPD diagnosis and were required to initiate mCOPD medication within 1 year of diagnosis.
The authors found that less than one-fourth (20.8%) of patients were considered adherent based on the proportion of days covered. In addition, they found significant differences between patients who were adherence and patients who were not adherent based on geographical location, comorbidity burden, and influenza vaccination status. Nonadherence patients were more likely to live in the south, had a greater comorbidity burden, and were less likely to have the recommended frequency of flu vaccinations.
Looking at adherence to other chronic conditions, the authors found that nonadherence to antidepressants, antihypertensives, oral antyhyperglycemics, beta-blockers, bisphosphonates, calcium channel blockers, diuretics, insulins, nonsteroidal anti-inflammatory medications, and statins were each associated with increases nonadherence to COPD medications. Meanwhile, nonadherence to anticoagulants and antianxiety medications was not associated with nonadherence to COPD medications.
The findings imply that factors impacting adherence do not change by medication type. As such, patient counseling tools could influence behavior to improve adherence regardless of the medication type, the authors determined.
“The results of this study suggest that there is a positive association between non-adherence (or adherence) to mCOPD medications and non-adherence (or adherence) to non-COPD medications, ie, patients that are likely to be non-adherent (or adherent) to mCOPD medication are also likely to be non-adherent (or adherent) to non-COPD medications,” the authors concluded.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More